Clinical Trial Detail

NCT ID NCT03834519
Title Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010)
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate adenocarcinoma

Therapies

Abiraterone + Prednisone

Enzalutamide

Olaparib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.